AMDL, Inc. Says Jade Pharmaceutical, Inc. Sales Network Now Covers All of China

TUSTIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- AMDL, Inc. , headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc., said today that Jade has completed development of a national sales network encompassing the entire nation of China.

Jade has expanded to include 75 full-time sales representatives in its in-house sales force, explains Frank Zheng, Managing Director. The balance of the nation is covered by distribution partners.

"The current focus is on 36 key Chinese markets, in central, southeastern, eastern, northeastern and southwest China," said Mr. Zheng. "Over the next 12 months, Jade plans on expanding its sales network by 100 - 150 new sales professionals who will be selling an expanded line of products. Within the next four years, Jade will have a significant presence in all 168 cities in China that have a population of more than one million people."

"This continued expansion of the sales force in a focused, logical way will allow Jade to take full advantage of a Chinese pharmaceutical market that is growing explosively," said Gary Dreher, AMDL CEO.

About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460

AMDL, Inc.

CONTACT: Mr. Paul Knopick, AMDL Investor Relations, Direct Line,+1-949-707-5365, or Voice Mail, +1-714-505-4460

Back to news